Zhikun Liu

Zhikun Liu

Auto-generated profile, based on publicly available information

Zhikun Liu

Zhejiang University School of Medicine, Hangzhou, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2020 in Cancer Communications
Verified
Journal Article
Open access
PDF file
YWYichao Wu
Yichao Wu
ZLZhikun Liu
Zhikun Liu
XXXiao Xu
Xiao Xu
Hepatocellular carcinoma (HCC) is one of the most prevalent and fatal digestive tumors. Treatment for this disease has been constraint by heterogeneity of this group of tumors, which has greatly limited the progress in personalized therapy. Although existing studies have revealed the genetic and epigenetic blueprints that drive HCCs, many of the molecular mechanisms that lead to HCCs remain elusive. Recent advances in techniques for studying functional genomics, such as genome sequencing and transcriptomic analyses, have led to the discovery of molecular mechanisms that participate in the initiation and evolution of HCC. Integrative multi‐omics analyses have identified several molecular subtypes of HCC associated with specific molecular characteristics and clinical outcomes. Deciphering similar molecular features among highly heterogeneous HCC patients is a prerequisite to implementation of personalized therapeutics. This review summarizes the current research progresses in precision therapy on the backbone of molecular subtypes of HCC.

15 February 2024 in Advanced Science
Verified
Journal Article
Open access
XHXin Hu
Xin Hu
GCGuanrong Chen
Guanrong Chen
YHYingchen Huang
Yingchen Huang
QCQiyang Cheng
Qiyang Cheng
JZJianyong Zhuo
Jianyong Zhuo
XXXiao Xu
Xiao Xu
Recent studies suggest that circular RNA (circRNA)‐mediated post‐translational modification of RNA‐binding proteins (RBP) plays a pivotal role in metastasis of hepatocellular carcinoma (HCC). However, the specific mechanism and potential clinical therapeutic significance remain vague. This study attempts to profile the regulatory networks of circRNA and RBP using a multi‐omics approach. Has_circ_0006646 (circ0006646) is an unreported circRNA in HCC and is associated with a poor prognosis. Silencing of circ0006646 significantly hinders metastasis in vivo. Mechanistically, circ0006646 prevents the interaction between nucleolin (NCL) and the E3 ligase tripartite motif‐containing 21 to reduce the proteasome‐mediated degradation of NCL via K48‐linked polyubiquitylation. Furthermore, the change of NCL expression is proven to affect the phosphorylation levels of multiple proteins and inhibit p53 translation. Moreover, patient‐derived tumor xenograft and lentivirus injection, which is conducted to simulate clinical treatment confirmed the potential therapeutic value. Overall, this study describes the integrated multi‐omics landscape of circRNA‐mediated NCL ubiquitination degradation in HCC metastasis and provides a novel therapeutic target.

8 December 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CLChangbiao Li
Changbiao Li
YWYichao Wu
Yichao Wu
KCKangchen Chen
Kangchen Chen
RCRonggao Chen
Ronggao Chen
SXShengjun Xu
Shengjun Xu
XXXiao Xu
Xiao Xu
Ferroptosis, which is driven by iron-dependent lipid peroxidation, plays an essential role in liver ischemia-reperfusion injury (IRI) during liver transplantation (LT). Gp78, an E3 ligase, has been implicated in lipid metabolism and inflammation. However, its role in liver IRI and ferroptosis remains unknown. Here, hepatocyte-specific gp78 knockout (HKO) or overexpressed (OE) mice were generated to examine the effect of gp78 on liver IRI, and a multi-omics approach (transcriptomics, proteomics, and metabolomics) was performed to explore the potential mechanism. Gp78 expression decreased after reperfusion in LT patients and mice with IRI, and gp78 expression was positively correlated with liver damage. Gp78 absence from hepatocytes alleviated liver damage in mice with IRI, ameliorating inflammation. However, mice with hepatic gp78 overexpression showed the opposite phenotype. Mechanistically, gp78 overexpression disturbed lipid homeostasis, remodeling polyunsaturated fatty acid (PUFA) metabolism, causing oxidized lipids accumulation and ferroptosis, partly by promoting ACSL4 expression. Chemical inhibition of ferroptosis or ACSL4 abrogated the effects of gp78 on ferroptosis and liver IRI. Our findings reveal a role of gp78 in liver IRI pathogenesis and uncover a mechanism by which gp78 promotes hepatocyte ferroptosis by ACSL4, suggesting the gp78-ACSL4 axis as a feasible target for the treatment of IRI-associated liver damage.

6 June 2018 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
ZLZhikun Liu
Zhikun Liu
QYQianwei Ye
Qianwei Ye
LWLingjiao Wu
Lingjiao Wu
FGFeng Gao
Feng Gao
HXHaiyang Xie
Haiyang Xie
XXXiao Xu
Xiao Xu

6 April 2023 in Biochemical Pharmacology
Verified
Journal Article
Closed access
YJYi Jing
Yi Jing
Tianhui HuTianhui Hu
Tianhui Hu
JYJun Yuan
Jun Yuan
ZLZhikun Liu
Zhikun Liu
MTMingtao Tao
Mingtao Tao
QXQingping Xiong
Qingping Xiong

1 January 2023 in Chinese Journal of Cancer Research
Verified
Journal Article
Closed access
YGYufeng Gu
Yufeng Gu
SXShengjun Xu
Shengjun Xu
ZWZhengxin Wang
Zhengxin Wang
JYJiayin Yang
Jiayin Yang
SZShusen Zheng
Shusen Zheng
XXXiao Xu
Xiao Xu
Liver transplantation (LT) is a highly curative therapy for patients with hepatocellular carcinoma (HCC). However, due to the shortage of donor livers and rapid progression of HCC, a majority of patients are dropped out from the waitlist. Recently, immunotherapy has shown great promise in the treatment of advanced HCC. However, the use of immunotherapy is limited in LT mainly due to the potentially increasing risk of graft rejection. One of the main challenges for researchers is the protection of donor graft from an immunotherapy-boosted immune response mounted by the host. Besides, the safety, availability, and costs of immunotherapy are other challenges that need to be addressed. Here, we reviewed the literature involving patients who received immunotherapy prior to transplant to avoid waitlist dropouts and following transplantation to prevent the progression of tumor recurrence and metastasis. Statistically, the incidence of rejection was 25.0% pre-transplant and 18.5% post-transplant. Based on the review of these clinical studies, we can conclude that conducting clinical trials on the safety and efficacy of currently available immunotherapy drugs and identifying novel immunotherapy targets through extensive research may be promising for patients who do not meet the selection criteria for LT and who experience post-transplant recurrence. To date, the clinical experience on the use of immunotherapy before or after LT comes from individual case studies. Although some of the reported results are promising, they are not sufficient to support the standardized use of immunotherapy in clinical practice.